, , 2015.
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer. 1 mars, vol.136, issue.5, pp.359-86, 2015. ,
, Melanoma of the Skin Cancer Stat Facts
PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges, Immunotherapy. juin, vol.8, issue.6, pp.733-779, 2016. ,
,
, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med. 28 juin, vol.366, issue.26, pp.2443-54, 2012.
Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies, Semin Oncol. juin, vol.42, issue.3, pp.429-464, 2015. ,
PD-L1 expression in cancer patients receiving anti PD ,
A systematic review and meta-analysis, Crit Rev Oncol Hematol. avr, vol.100, pp.88-98, 2016. ,
Association of PD-1, p.1 ,
, other features of the tumor immune microenvironment with response to anti-PD-1 therapy, Clin Cancer Res Off J Am Assoc Cancer Res, vol.20, pp.5064-74, 2014.
PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics ,
, Ann Oncol Off J Eur Soc Med Oncol. déc, vol.25, issue.12, pp.2433-2475, 2014.
Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis. Medicine (Baltimore), vol.96, p.6369, 2017. ,
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma, Cancer. 1 avr, vol.116, issue.7, pp.1757-66, 2010. ,
Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites, Clin Cancer Res Off J Am Assoc Cancer Res. 1 juill, vol.21, issue.13, p.60, 2015. ,
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, vol.515, issue.7528, p.5637, 2014. ,
PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.515, issue.7528, pp.568-71, 2014. ,
Classifying Cancers Based on T-cell Infiltration and PD-L1, Cancer Res. 1 juin, vol.75, issue.11, p.213945, 2015. ,
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape, Sci Transl Med. 28 mars, vol.4, issue.127, pp.127-164, 2012. ,
,
, Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med. 11 juill, vol.369, issue.2, p.33, 2013.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, N Engl J Med. 2 juill, vol.373, issue.1, p.2334, 2015. ,
Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med. 22 janv, vol.372, issue.4, p.32030, 2015. ,
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Lancet Oncol. avr, vol.16, issue.4, p.37584, 2015. ,
Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays, Thyroid Off J Am Thyroid Assoc. mai, vol.24, issue.5, p.85866, 2014. ,
Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature. 11 juill, vol.499, issue.7457, p.2148, 2013. ,
Molecular mechanisms of T cell co-stimulation and co-inhibition, Nat Rev Immunol. avr, vol.13, issue.4, p.42, 2013. ,
Adaptive: PD-L1-mediated immune resistance by melanoma. Oncoimmunology, vol.4, p.1029704, 2015. ,
PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development, JAMA Oncol. janv, 2016. ,
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials, J Clin Oncol Off J Am Soc Clin Oncol. déc, vol.28, issue.3, pp.4102-4111, 2015. ,
Prognostic significance of tumor infiltrating lymphocytes in melanoma, Am Surg. févr, vol.77, issue.2, p.92, 2011. ,
Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy, Pathology (Phila). févr, vol.48, issue.2, p.87, 2016. ,
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma, Cancer. 1 avr, vol.77, issue.7, p.130310, 1996. ,
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma, J Clin Invest. 1 sept, vol.126, issue.9, p.344752, 2016. ,
,
, Mutational Landscape and Sensitivity to Immune Checkpoint Blockers, Clin Cancer Res Off J Am Assoc Cancer Res. 1 sept, vol.22, issue.17, pp.4309-4330, 2016.
, Je promets et je jure d'être fidèle aux lois de l'Honneur et de la probité dans l'exercice de la Médecine
, Je donnerais mes soins gratuitement à l'indigent et n'exigerai jamais un salaire au dessus de mon travail
, Admis dans l'intimité des maisons, mes yeux n'y verront pas ce qui s'y passe
, Je ne permettrai pas que des considérations de religion, de nation, de race, de parti ou de classe sociale viennent s'interposer entre mon Devoir et mon Patient
, Je garderai le respect absolu de la vie humaine. Même sous la menace
, Que les hommes m'accordent leur estime si je suis fidèle à mes promesses, Que je sois couvert d'opprobre et méprisé de mes confrères si j'y manque